

# Review of: "Resectable Pancreatic Cancer With Peritoneal Metastases: Is Cytoreduction Combined With Hipec Effective and When?"

Christopher Månsson<sup>1</sup>

<sup>1</sup> Uppsala University

Potential competing interests: No potential competing interests to declare.

I have with great interest read this original article regarding HIPEC for peritoneal metastases during pancreatic cancer by Tentes et al. This is an interesting topic for a dreaded disease with a dismal prognosis. However, I have several questions which need to be addressed.

1. Firstly, I don't like a title with a question that is not answered. When should they be treated? Rewrite and be clear that this is a case series.
2. Obviously, this is a highly selected group of patients, and this needs to be much clearer. The majority of the patients have a distal tumour and are younger than the average pancreatic cancer patient. The selection must be crystal clear. Which patients were treated, and which were not? How were they referred to your center?
3. Several patients had undergone a resection before. How long until reoperation with HIPEC? Any neoadjuvant treatment?
4. Since English is not my native language, I cannot give an assessment of the language; however, a language check by a native speaker is always good if English is not one's first language.

This case series obviously has a selection bias that needs to be clearly addressed. However, I still find these results interesting since they include patients with long-term survival.

Kind regards,